Table 4.

Coefficient estimates for landmark models applied to prostate cancer data.

		LM2		LM3		LM4		LMInt4
	Covariate	Coef.	SE	Coef.	SE	Coef.	SE	Coef.	SE
β(τ)	CF	3.317	1.204	2.065	0.279	3.921	1.210	3.406	2.972
	CF*τ	−0.439	0.427			−0.460	0.409	−0.220	0.374
	CF*τ2	0.020	0.034			0.021	0.033	0.006	0.031
ω(τ)	CF*(t − τ)			−0.513	0.190	−0.562	0.175	−0.341	0.188
	CF*(t − τ)2			0.082	0.051	0.093	0.045	0.062	0.049
θ(τ)	τ	−0.056	0.018	−0.043	0.019	−0.069	0.023	−0.073	0.022
	τ2	0.004	0.001	0.001	0.002	0.004	0.002	0.004	0.002
ζ	Age	0.080	0.012	0.080	0.012	0.080	0.012	0.082	0.013
	log(PSA + 1)	0.227	0.111	0.234	0.110	0.227	0.111	0.246	0.112
	Gleason score	0.292	0.091	0.288	0.091	0.289	0.091	0.269	0.094
	Stage T2–T3	0.040	0.168	0.054	0.168	0.042	0.167	0.057	0.171
	Comorbidities 1–2	0.414	0.171	0.395	0.171	0.420	0.170	0.474	0.174
	Comorbidities ≥3	1.214	0.248	1.207	0.247	1.214	0.247	1.230	0.252
ζZ(τ)	CF*Age							−0.015	0.024
	CF*log(PSA + 1)							−0.577	0.366
	CF*Gleason score							0.336	0.252
	CF*Stage T2–T3							0.372	0.655
	CF*Comorbidities 1–2							−1.116	0.457
	CF*Comorbidities ≥3							−0.148	0.708
Log-likelihood			−11,135		−11,143		−11,132		−11,118
AIC			22,292		22,308		22,289		22,273